Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT103A and Selinexor in Relapsed/Refractory Extramedullary Multiple Myeloma
NCT05201118Phase 1Unknown
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of equecabtagene autoleucel in multiple myeloma (MM). Primary endpoints: Progression-Free Survival at 1 year, Objective Response Rate at 1 year and 1 more. Status: unknown.
02
Drugs
equecabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05201118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201118.